Skip to main content

Currently Skimming:

1 Introduction and Themes of the Workshop
Pages 1-6

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 1...
... for a specific indication. Because data have already been acquired, repurposing a drug can save time and money compared with the process of developing a drug de novo; repurposed drugs are generally approved in shorter timeframes (3 to 12 years)
From page 2...
... hosted a workshop on June 24, 2013, in Washington, DC, to assess the current landscape of drug repurposing activities in industry, academia, and government. Stakeholders, including government officials, pharmaceutical company representatives, academic researchers, regulators, funders, and patients, were invited to present their perspectives and to participate in workshop discussions.
From page 3...
... Though orphan drugs are used by relatively few patients, they can still be profitable for companies and have been a major target of repurposing and repositioning efforts. Barriers to drug repositioning are also discussed, including reluctance to explore alternate indications, the need to update clinical regulatory documents, and considerations relating to the limited patent life of repurposed drugs.
From page 4...
... Finally, the drug development process is considered, with a particular focus on the idea that disease indications need to be re-evaluated throughout the discovery, development, and life-cycle management of a compound. Chapter 5 presents research and policy initiatives that have been undertaken to encourage repurposing activities; such initiatives often take the form of partnerships involving academic researchers, companies, and government agencies.
From page 5...
... INTRODUCTION AND THEMES OF THE WORKSHOP 5 speakers and many participants who spoke stated that drug repurposing has the potential to change the lives of patients by providing another path for drug development.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.